Просмотр новости
Найдите то, что Вас интересует
Спутники
РН
SpaceX
Роскосмос
NASA
Tumor Ablation Market by Technology (Radiofrequency, Microwave, Cryoablation, HIFU), Product (Systems, Consumables), Application (Liver, Lung, Kidney, Bone Cancer), Procedure (Surgical, Laparoscopic, Percutaneous), and End User - Global Forecast to 2031..., Market Research Report: MarketsandMarkets
Дата публикации: 03-08-2026 00:00:00
Основное содержимое страницы с новостью.
Tumor Ablation Market by Technology (Radiofrequency, Microwave, Cryoablation, HIFU), Product (Systems, Consumables), Application (Liver, Lung, Kidney, Bone Cancer), Procedure (Surgical, Laparoscopic, Percutaneous), and End User - Global Forecast to 2031
2026-2031
FORECAST PERIOD
TUMOR ABLATION MARKET SIZE, SHARE & GROWTH SNAPSHOT
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
The global tumor ablation market is projected to grow from USD 1.10 billion in 2026 to USD 1.89 billion by 2031, at a CAGR of 11.4% during the forecast period. The market was valued at USD 0.99 billion in 2025. The tumor ablation market is expected to experience stable growth because of the rise in cancer cases, along with the need for minimally invasive treatment methods that provide effective tumor management while minimizing patient trauma. The increasing number of liver, lung, kidney, bone, and prostate cancers has promoted the uptake of the ablation therapy process in order to provide curative and palliative treatment options, especially for those patients who cannot undergo conventional surgeries. Innovations in tumor ablation through processes such as RFA, MWA, cryoablation, laser ablation, HIFU, and IRE have improved treatment efficacy and safety, promoting adoption among physicians. Apart from this, factors such as the development of interventional oncology programs, the availability of cancer facilities, favorable reimbursement policies in developed countries, and healthcare investments are also fueling the growth of the market.
KEY TAKEAWAYS
-
MARKET SNAPSHOT:
Base Year Market Size (2025): USD 0.99 Billion
Current Market Size (2026): USD 1.10 Billion
Forecast Market Size (2031): USD 1.89 Billion
CAGR (2026–2031): 11.4% -
SEGMENT LEADERSHIP:
Regional Leader: North America accounted for 42.5–44.5% of the tumor ablation market in 2025.
Technology Leader: Radiofrequency ablation segment accounted for 65–67% in 2025.
Product Leader: Consumables segment accounted for the larger share of the tumor ablation market in 2025.
Procedure Leader: Surgical ablation segment accounted for the larger share of the tumor ablation market in 2025.
End User Leader: Hospitals & clinics held 70.5–72.5% of the global market. -
MARKET OUTLOOK & COMPETITIVE LANDSCAPE:
Medtronic was recognized as a star player due to its established strong product portfolio.
Creo Medical has been recognized as a prominent player among startups and SMEs due to its offerings and strategic initiatives.
The tumor ablation market is witnessing robust growth, primarily driven by the increasing global burden of cancer and the growing preference for minimally invasive treatment approaches. Rising cases of liver, lung, kidney, bone, and prostate cancers have accelerated the adoption of tumor ablation as an effective treatment option, particularly for patients who are ineligible for conventional surgery due to age, comorbidities, or tumor location. Ongoing advancements in ablation technologies, including radiofrequency ablation (RFA), microwave ablation (MWA), cryoablation, laser ablation, high-intensity focused ultrasound (HIFU), and irreversible electroporation (IRE), have significantly improved treatment accuracy, procedural safety, and patient outcomes, leading to wider clinical acceptance. Furthermore, the expansion of interventional oncology services, increasing number of specialized cancer care centers, supportive reimbursement frameworks, and growing investments in healthcare infrastructure are fueling market growth. The rising shift toward outpatient and image-guided minimally invasive procedures, combined with greater awareness of the clinical effectiveness and cost benefits of tumor ablation, is further driving the adoption of tumor ablation devices and consumables across healthcare settings.
TRENDS & DISRUPTIONS IMPACTING CUSTOMERS' CUSTOMERS
The tumor ablation market is undergoing a significant transformation as advancements in minimally invasive technologies, expanding clinical applications, and evolving healthcare delivery models reshape treatment approaches. While traditional revenue has been driven by established ablation technologies such as radiofrequency ablation (RFA), microwave ablation (MWA), cryoablation, high-intensity focused ultrasound (HIFU), and consumables, future growth is expected to be fueled by next-generation innovations including AI-enabled treatment planning, robotic-assisted tumor ablation, image fusion and real-time image-guided ablation, histotripsy, and smart ablation systems with temperature monitoring. At the same time, hospitals, cancer centers, ambulatory surgery centers (ASCs), and specialty clinics are increasingly focused on expanding minimally invasive oncology programs, improving procedural efficiency, reducing hospital stays, and enabling outpatient care. These trends are expected to enhance patient outcomes, lower treatment costs, improve operational efficiency, and create new revenue opportunities for market participants, driving the continued evolution of the global tumor ablation market.
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
MARKET DYNAMICS
OPPORTUNITIES
Impact
Level
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
The increasing global incidence of cancer is one of the primary drivers of the tumor ablation market. The growing prevalence of liver, lung, kidney, bone, and prostate cancers has led to a greater demand for effective and minimally invasive treatment options. Tumor ablation is increasingly being adopted as an alternative or complementary therapy to surgery, particularly for patients with early-stage tumors or those who are not suitable candidates for surgical resection. Rising awareness of early cancer diagnosis, coupled with an aging population and lifestyle-related risk factors, is further increasing the number of patients requiring tumor ablation procedures, thereby driving market growth.
The high cost of tumor ablation systems and associated procedures remains a significant restraint for market growth. Advanced ablation generators, probes, electrodes, cryoprobes, and microwave antennas require substantial capital investment, making them less accessible for small hospitals and healthcare facilities, particularly in developing countries. In addition, procedure-related expenses, maintenance costs, and the need for specialized infrastructure increase the overall treatment cost. Limited reimbursement in certain regions further restricts patient access, slowing the adoption of tumor ablation technologies.
The expansion of cancer care centers and hospitals presents a significant opportunity for the tumor ablation market. Governments and private healthcare organizations are investing heavily in strengthening oncology infrastructure to address the growing cancer burden. The establishment of dedicated cancer centers, expansion of interventional oncology departments, and increasing availability of minimally invasive treatment facilities are creating favorable conditions for the adoption of tumor ablation technologies. Furthermore, improving healthcare access in emerging economies and rising investments in advanced medical equipment are expected to generate new growth opportunities for manufacturers of tumor ablation systems and consumables.
A shortage of skilled interventional radiologists and oncologists poses a major challenge to the growth of the tumor ablation market. Successful tumor ablation procedures require experienced clinicians with expertise in image-guided interventions, precise probe placement, and patient selection. Many developing regions face a limited availability of trained specialists, which restricts the adoption of advanced ablation technologies despite increasing demand. Additionally, the need for continuous training to keep pace with evolving ablation techniques and technologies further limits procedural capacity and may affect treatment outcomes, posing a challenge to broader market expansion.
TUMOR ABLATION MARKET: COMMERCIAL USE CASES ACROSS INDUSTRIES
| COMPANY | USE CASE DESCRIPTION | BENEFITS |
|---|---|---|
|
|
Provides radiofrequency (RF) ablation systems that use controlled thermal energy to destroy solid tumors by inducing localized coagulative necrosis. These systems are widely used for the minimally invasive treatment of liver, kidney, lung, bone, and soft tissue tumors through surgical, laparoscopic, or percutaneous procedures in hospitals and cancer centers. | Delivers precise and controlled tumor destruction while preserving surrounding healthy tissue, enables minimally invasive treatment, reduces blood loss and hospital stay, supports faster patient recovery, and provides reliable clinical outcomes across multiple tumor indications. |
|
|
Provides cryoablation systems that utilize extremely low temperatures to freeze and destroy cancerous tissue. These systems are commonly used to treat kidney, liver, lung, bone, and soft tissue tumors through image-guided, minimally invasive procedures performed in interventional radiology and oncology departments. | Enables precise visualization of the ablation zone, minimizes damage to adjacent healthy tissue, reduces procedural pain, supports preservation of critical structures, shortens recovery time, and delivers effective local tumor control with predictable treatment outcomes. |
|
|
Provides robotic high-intensity focused ultrasound (HIFU) systems for non-invasive focal treatment of localized prostate cancer. The platform combines robotic targeting, real-time imaging, and focused ultrasound energy to precisely ablate cancerous tissue without surgical incisions, making it suitable for urology and specialized cancer centers | Offers completely incision-free treatment, preserves surrounding healthy tissue and urinary/sexual function, improves targeting accuracy through robotic assistance, reduces procedure-related complications, shortens recovery time, and enhances patient quality of life following treatment |
|
|
Provides radiofrequency ablation electrodes designed to accurately deliver RF energy from the generator to targeted tumor tissue during ablation procedures. These disposable electrodes are used in conjunction with RF ablation systems for treating liver, kidney, lung, bone, and other solid tumors in minimally invasive oncology procedures. | Ensures efficient and uniform energy delivery, improves ablation accuracy, supports consistent lesion formation, enhances procedural safety, minimizes collateral tissue damage, and contributes to successful local tumor destruction with reliable clinical performance |
|
|
Provides radiofrequency ablation systems that generate controlled thermal energy for the treatment of solid tumors during open, laparoscopic, and percutaneous procedures. These systems are utilized in oncology, general surgery, and interventional radiology settings to perform minimally invasive tumor ablation across multiple cancer indications | Provides stable and precise energy delivery for effective tumor destruction, improves procedural efficiency, supports minimally invasive treatment, reduces post-operative complications and recovery time, and offers dependable performance for a broad range of tumor ablation procedures |
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
MARKET ECOSYSTEM
The global tumor ablation market ecosystem comprises medical device manufacturers, healthcare providers, and regulatory authorities that collectively drive the development, adoption, and commercialization of tumor ablation technologies. Leading manufacturers such as Medtronic, Boston Scientific, CONMED, AngioDynamics, Stryker, EDAP TMS (Focal One), and Bioventus focus on developing advanced tumor ablation systems, generators, probes, electrodes, cryoprobes, HIFU platforms, and related consumables to improve treatment precision and clinical outcomes. These technologies are primarily adopted by hospitals, cancer centers, and specialty clinics, where multidisciplinary oncology teams perform minimally invasive tumor ablation procedures for various solid tumors. The market is further supported by regulatory agencies, including the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), Medicines and Healthcare products Regulatory Agency (MHRA, UK), Therapeutic Goods Administration (TGA, Australia), and other national health authorities, which ensure the safety, efficacy, and quality of tumor ablation devices through stringent approval processes. Collaboration among manufacturers, healthcare institutions, and regulatory bodies fosters continuous technological innovation, expands clinical adoption, and supports sustained growth in the global tumor ablation market.
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
MARKET SEGMENTS
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
Radiofrequency ablation (RFA) accounts for the largest share of the tumor ablation market by technology owing to its long-standing clinical acceptance, well-established safety profile, and effectiveness in treating a wide range of solid tumors, including those affecting the liver, kidney, lung, bone, and soft tissues. The technology is extensively adopted because it provides precise thermal destruction of tumor tissue through a minimally invasive approach while minimizing damage to surrounding healthy tissue. Its high clinical success rates, reduced recovery time, lower risk of complications, and relatively cost-effective nature compared to several other ablation technologies have contributed to its widespread utilization. Furthermore, the extensive installed base of RFA generators, broad availability of compatible electrodes and consumables, strong physician familiarity, and recommendations in clinical practice guidelines for multiple tumor indications continue to reinforce RFA's leadership in the global tumor ablation market.
Consumables represent the largest share of the tumor ablation market by product owing to their essential role in every ablation procedure and their recurring usage across multiple treatments. Products such as radiofrequency electrodes, microwave antennas, cryoprobes, laser fibers, disposable applicators, grounding pads, and related accessories are typically single-use or have limited reuse to maintain sterility, procedural safety, and consistent clinical performance. As the volume of tumor ablation procedures continues to rise globally, healthcare facilities require a continuous supply of these consumables, generating a steady and recurring revenue stream for manufacturers. Furthermore, the growing adoption of minimally invasive ablation techniques, increasing number of oncology and interventional radiology procedures, and ongoing introduction of technologically advanced consumables with enhanced precision and safety features continue to strengthen the dominance of the consumables segment in the global tumor ablation market.
Surgical ablation represents the largest share of the tumor ablation market by procedure due to its widespread use in the treatment of patients undergoing open or minimally invasive cancer surgeries. Surgical ablation enables physicians to directly access tumors, making it particularly suitable for treating larger, complex, or difficult-to-reach lesions while allowing precise probe placement and complete tumor destruction. It is commonly performed either as a standalone procedure or in combination with tumor resection to improve treatment outcomes, especially for liver, kidney, lung, and bone tumors. The availability of advanced ablation systems compatible with surgical workflows, increasing adoption of minimally invasive surgical techniques, and the growing number of cancer surgeries performed globally further contribute to the dominance of the surgical ablation segment. Additionally, surgeons' familiarity with ablation technologies and the ability to treat multiple lesions during a single surgical procedure continue to support the segment's leading market position.
Liver cancer holds the largest share of the tumor ablation market by application, primarily due to the extensive adoption of ablation therapies for treating both primary liver malignancies and selected metastatic liver lesions. Tumor ablation has become a preferred treatment option for patients with small, localized tumors, particularly those who are unsuitable for surgical resection or liver transplantation because of impaired liver function, advanced age, or other underlying health conditions. Technologies such as radiofrequency ablation (RFA), microwave ablation (MWA), cryoablation, and irreversible electroporation (IRE) are widely employed for liver tumors because they provide effective local tumor destruction while preserving healthy liver tissue. Furthermore, the rising global prevalence of liver cancer, growing preference for minimally invasive treatment modalities, strong clinical evidence supporting ablation in the management of early-stage hepatocellular carcinoma, and the increasing availability of specialized interventional oncology facilities continue to drive the leadership of the liver cancer segment in the global tumor ablation market.
Hospitals and clinics represent the largest share of the tumor ablation market due to their comprehensive cancer care capabilities, advanced procedural infrastructure, and availability of multidisciplinary oncology teams. These healthcare settings are equipped with specialized operating rooms, interventional radiology suites, and experienced clinicians required to perform a wide range of tumor ablation procedures safely and effectively. Hospitals and clinics also manage a high volume of cancer patients, including complex cases requiring integrated treatment approaches involving surgery, chemotherapy, radiation therapy, and ablation. Furthermore, favorable reimbursement policies, access to advanced ablation technologies, and increasing investments in oncology infrastructure have strengthened the adoption of tumor ablation systems in these facilities. The growing number of minimally invasive cancer procedures performed in hospitals and clinics continues to reinforce their dominant position in the global tumor ablation market.
REGION
Asia Pacific to be fastest-growing region in global tumor ablabtion market during forecast period
The Asia Pacific (APAC) region is projected to register the highest CAGR in the global tumor ablation market during the forecast period, driven by the rapidly increasing cancer burden, expanding healthcare infrastructure, and growing adoption of minimally invasive treatment procedures. Countries such as China, India, Japan, and South Korea are witnessing rising investments in oncology care, increasing establishment of specialized cancer hospitals and interventional radiology centers, and improved access to advanced medical technologies. The region also benefits from a large patient population, growing healthcare expenditure, supportive government initiatives for cancer diagnosis and treatment, and increasing awareness of minimally invasive therapies among physicians and patients. Furthermore, the expansion of private healthcare providers, improving reimbursement frameworks in several countries, and the entry of global medical device manufacturers into emerging APAC markets are expected to accelerate the adoption of tumor ablation systems and consumables, making the region the fastest-growing market globally.
TUMOR ABLATION MARKET: COMPANY EVALUATION MATRIX
In the tumor ablation market matrix, Medtronic (Star) holds a strong share due to its global presence, advanced tumor ablation product portfolio, extensive installed base, strong physician adoption, and continuous investment in innovative technologies and solutions. Varian (Emerging Leader) is a prominent player because of its growing focus on minimally invasive and energy-based technologies, cost-effective solutions, strong expertise in endoscopy, and increasing adoption of its advanced tumor ablation systems across hospitals and ambulatory surgical centers.
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
KEY MARKET PLAYERS
MARKET SCOPE
| REPORT METRIC | DETAILS |
|---|---|
| Market Size in 2025 (Value) | USD 0.99 Billion |
| Market Size in 2026 (Value) | USD 1.10 Billion |
| Market Forecast in 2031 (Value) | USD 1.89 Billion |
| Growth Rate | CAGR of 11.4% from 2026-2031 |
| Years Considered | 2024-2031 |
| Base Year | 2025 |
| Forecast Period | 2026-2031 |
| Units Considered | Value (USD Million/Billion), Volume (Million Units) |
| Report Coverage | Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, and Trends |
| Segments Covered |
|
| Regions Covered | North America, Asia Pacific, Europe, Latin America, and the Middle East & Africa |
WHAT IS IN IT FOR YOU: TUMOR ABLATION MARKET REPORT CONTENT GUIDE
DELIVERED CUSTOMIZATIONS
We have successfully delivered the following deep-dive customizations:
| CLIENT REQUEST | CUSTOMIZATION DELIVERED | VALUE ADDS |
|---|---|---|
| Product Analysis | Comparison of top ablation products:Radiofrequency Ablation, Cryoablation, Microwave Ablation,High-Intensity Focused Ultrasound (HIFU) |
|
| Company Information |
|
Insights on revenue shifts towards emerging applications and device innovations. |
| Geographic Analysis |
|
Country level demand mapping for new product launches and localization strategy planning |
RECENT DEVELOPMENTS
- July 2026 : IceCure announced the commercial adoption of its ProSense Cryoablation in Brazil, following clearance.
- February 2026 : AngioDynamics announced expanded European indications for its NanoKnife System to include soft tissue ablation for tumors of the liver, pancreas, kidney, and prostate, including in patients with intermediate-risk prostate cancer.
Table of Contents
Exclusive indicates content/data unique to MarketsandMarkets and not available with any competitors.
4
MARKET OVERVIEW
Covers the key developments, trend analysis, and actionable insights to support strategic planning and positioning.4.3
UNMET NEEDS AND WHITE SPACES
4.4
INTERCONNECTED MARKETS AND CROSS-SECTOR OPPORTUNTIES
4.5
STRATEGIC MOVES BY TIER-1/2/3 PLAYERS
5
INDUSTRY TRENDS
Summarizes the competitive environment, macro signals, and segment-level movements driving market outcomes.5.1
PORTER’S FIVE FORCES ANALYSIS
5.2
MACROECONOMIC OUTLOOK
5.2.2
GDP TRENDS AND FORECAST
5.2.3
TRENDS IN ABLATION TECHNOLOGY INDUSTRY
5.2.4
TRENDS IN INTERVENTIONAL ONCOLOGY INDUSTRY
5.3
SUPPLY CHAIN ANALYSIS
5.6.1
AVERAGE SELLING PRICE TREND, BY REGION (2023-2025)
5.6.2
AVERAGE SELLING PRICE TREND, BY KEY PLAYER (2023-2025)
5.8
KEY CONFERENCES AND EVENTS, 2026–2027
5.9
TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
5.10
INVESTMENT AND FUNDING SCENARIO
5.12
IMPACT OF 2025 US TARIFFS–TUMOR ABLATION MARKET
5.12.3
PRICE IMPACT ANALYSIS
5.12.4
IMPACT ON COUNTRIES/REGIONS
5.12.5
IMPACT ON END-USE INDUSTRIES
6
TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS
6.1
KEY EMERGING TECHNOLOGY
6.2
COMPLEMENTARY TECHNOLOGY
6.3
TECHNOLOGY/PRODUCT ROADMAP
6.6
IMPACT OF AI/GEN AI ON TUMOR ABLATION MARKET
6.6.1
TOP USE CASES AND MARKET POTENTIAL
6.6.2
BEST PRACTICES IN TUMOR ABLATION PROCESSING
6.6.3
CASE STUDIES OF AI IMPLEMENTATION IN THE TUMOR ABLATION MARKET
6.6.4
INTERCONNECTED ADJACENT ECOSYSTEM AND IMPACT ON MARKET PLAYERS
6.6.5
CLIENTS’ READINESS TO ADOPT GENERATIVE AI IN TUMOR ABLATION MARKET
7.1
REGIONAL REGULATIONS AND COMPLIANCE
7.1.1
REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
7.2
CERTIFICATIONS, LABELING, ECO-STANDARDS
8
CUSTOMER LANDSCAPE & BUYER BEHAVIOR
8.1
DECISION-MAKING PROCESS
8.2
BUYER STAKEHOLDERS AND BUYING EVALUATION CRITERIA
8.3
ADOPTION BARRIERS & INTERNAL CHALLENGES
8.4
UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES
9
TUMOR ABLATION MARKET, BY TECHNOLOGY (MARKET SIZE & FORECAST TO 2031 – IN VALUE, USD MILLION)
9.2
RADIOFREQUENCY ABLATION
9.4
HIGH-INTENSITY FOCUSED ULTRASOUND (HIFU) ABLATION
10
TUMOR ABLATION MARKET, BY PRODUCT (MARKET SIZE & FORECAST TO 2031 – IN VALUE, USD MILLION & VOLUME, IN UNITS)
10.2.1
RADIOFREQUENCY ABLATION SYSTEMS
10.2.2
MICROWAVE ABLATION SYSTEMS
10.2.3
HIGH-INTENSITY FOCUSED ULTRASOUND (HIFU)
10.2.4
CRYOABLATION SYSTEMS
10.3
CONSUMABLES AND ACCESSORIES
10.2.1.1
RF ABLATION PROBES
10.2.1.2
MICROWAVE ABLATION PROBES
10.2.1.3
OTHER PROBES/ ELECTRODES
10.2.2
OTHER CONSUMABLES AND ACCESSORIES
11
TUMOR ABLATION MARKET, BY PROCEDURE (MARKET SIZE & FORECAST TO 2031 – IN VALUE, USD MILLION)
11.3
LAPAROSCOPIC ABLATION
11.4
PERCUTANEOUS ABLATION
12
TUMOR ABLATION MARKET, BY APPLICATION (MARKET SIZE & FORECAST TO 2031 – IN VALUE, USD MILLION)
13
TUMOR ABLATION MARKET, BY END USER (MARKET SIZE & FORECAST TO 2031 – IN VALUE, USD MILLION)
13.4
AMBULATORY SURGICAL CENTERS
14
TUMOR ABLATION MARKET, BY REGION (MARKET SIZE & FORECAST TO 2031 – IN VALUE, USD MILLION)
14.4.6
REST OF ASIA PACIFIC
14.5.3
REST OF LATIN AMERICA
14.6
MIDDLE EAST & AFRICA
14.6.2
REST OF MIDDLE EAST & AFRICA
15.2
KEY PLAYER STRATEGIES/RIGHT TO WIN
15.3
REVENUE SHARE ANALYSIS OF KEY PLAYERS,2024
15.4
MARKET SHARE ANALYSIS,
15.5
BRAND/PRODUCT COMPARATIVE ANALYSIS
15.6
COMPANY EVALUATION MATRIX: KEY PLAYERS,
15.6.5
COMPANY FOOTPRINT: KEY PLAYERS,
15.6.5.1
COMPANY FOOTPRINT
15.6.5.2
REGION FOOTPRINT
15.6.5.3
TECHNOLOGY FOOTPRINT
15.6.5.4
PRODUCT FOOTPRINT
15.6.5.5
PROCEDURE FOOTPRINT
15.6.5.6
APPLICATION FOOTPRINT
15.6.5.7
END-USER FOOTPRINT
15.7
COMPANY EVALUATION MATRIX: STARTUPS/SMES,
15.7.1
PROGRESSIVE COMPANIES
15.7.2
RESPONSIVE COMPANIES
15.7.5
COMPETITIVE BENCHMARKING: STARTUPS/SMES,
15.7.5.1DETAILED LIST OF KEY STARTUPS/SMES
15.7.5.2COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES
15.8
COMPETITIVE SCENARIO
15.8.4
OTHER DEVELOPMENTS
15.9
R&D ASSESSMENT OF KEY PLAYERS
15.10
COMPANY VALUATION AND FINANCIAL METRICS
16.1.3
BOSTON SCIENTIFIC CORPORATION
16.1.4
VARIAN MEDICAL SYSTEMS, INC.
16.1.5
OLYMPUS CORPORATION
16.1.7
CONMED CORPORATION
16.1.10
CANYON MEDICAL INC.
16.1.12
CHONGQING HAIFU MEDICAL TECHNOLOGY CO., LTD.
16.2.1
MEDSPHERE SHANGHAI
16.2.4
MINIMAX MEDICAL HOLDING GROUP
16.2.5
RF MEDICAL CO., LTD.
17.1.1.1
KEY DATA FROM SECONDARY SOURCES
17.1.2.1
KEY DATA FROM PRIMARY SOURCES
17.1.2.2
KEY PRIMARY PARTICIPANTS
17.1.2.3
BREAKDOWN OF PRIMARY INTERVIEWS
17.1.2.4
KEY INDUSTRY INSIGHTS
17.2
MARKET SIZE ESTIMATION
17.2.1
BOTTOM-UP APPROACH
17.2.3
BASE NUMBER CALCULATION
17.3
MARKET FORECAST APPROACH
17.6
RESEARCH ASSUMPTIONS
17.7
RESEARCH LIMITATIONS AND RISK ASSESSMENT
18.1
INSIGHTS OF INDUSTRY EXPERTS
18.3
KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
18.4
CUSTOMIZATION OPTIONS
Methodology
This study involved four major activities in estimating the current tumor ablation market size. First, extensive secondary research was conducted to gather information on the market, including related and parent markets. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. After that, market breakdown and data triangulation were used to estimate the market size of segments and subsegments.
Secondary ResearchThe secondary research process involved the widespread use of secondary sources, directories, databases (such as Bloomberg Businessweek, Factiva, and D&B Hoovers), white papers, annual reports, Companies House documents, investor presentations, and SEC filings. Secondary research was used to identify and collect information useful for the extensive, technical, market-oriented, and commercial study of the tumor ablation market. It was also used to obtain important information about key players and market classification and segmentation according to industry trends to the bottom-most level, as well as key developments related to market and technology perspectives. A database of the key industry leaders was also prepared using secondary research.
Primary ResearchIn the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side include industry experts such as CEOs, vice presidents, marketing and sales directors, technology & innovation directors, and related key executives from various key companies and organizations operating in the tumor ablation market. The primary sources from the demand side included industry experts, purchase & sales managers, doctors, and personnel from research organizations. Primary research was conducted to validate the market segmentation, identify key players in the market, and gather insights on key industry trends and key market dynamics.
A breakdown of the primary respondents for the tumor ablation market is provided below:
Note 1: C-level primaries include CEOs, CFOs, COOs, and VPs.
Note 2: Other designations include sales managers, marketing managers, business development managers, product managers, distributors, and suppliers.
Note 3: Companies are classified into tiers based on their total revenue. As of 2023, Tier 1 = >USD 10.00 billion, Tier 2 = USD 1.00 billion to USD 10.00 billion, and Tier 3 = <USD 1.00 billion.
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
Tumor Ablation Market : Top-Down and Bottom-Up Approach
For the global market value, annual revenues were calculated based on the revenue mapping of major product manufacturers and OEMs active in the global tumor ablation market. All the major product manufacturers were identified at the global and/or country/regional level. Revenue mapping for the respective business segments/sub-segments was done for the major players. Also, the global tumor ablation market was split into various segments and sub-segments based on:
- List of major players operating in the products market at the regional and/or country level
- Product mapping of various tumor ablation manufacturers at the regional and/or country level
- Mapping of annual revenue generated by listed major players from tumor ablation (or the nearest reported business unit/product category)
- Revenue mapping of major players
- Extrapolation of the revenue mapping of the listed major players to derive the global market value of the respective segments/subsegments
- Summation of the market value of all segments/subsegments to arrive at the global tumor ablation market.
Data Triangulation
After arriving at the overall size of the global tumor ablation market through the above-mentioned methodology, this market was split into several segments and subsegments. The data triangulation and market breakdown procedures were employed, wherever applicable, to complete the overall market engineering process and arrive at the exact market value data for the key segments and subsegments. The extrapolated market data was triangulated by studying various macro indicators and regional trends from both demand- and supply-side participants.
Market Definition
Tumor ablation is a minimally invasive surgical procedure used to remove or destroy cancerous tissue from the affected area as part of cancer management and treatment. The targeted tissue is subjected to ablating energy through surgical, laparoscopic, or percutaneous methods. This technique is commonly used for treating liver, bone, lung, kidney, prostate, and other types of cancer.
Key Stakeholders
- Tumor ablation system and electrode manufacturers, suppliers, and providers
- Contract research organizations (CROs)
- Research & development (R&D) companies
- Academic & research institutions
- Regulatory agencies
- Contract manufacturing organizations (CMOs)
- Environmental & safety regulatory bodies
- Hospitals & clinics
- Interventional radiologists
Report Objectives
- To define, describe, and forecast the tumor ablation market by technology, product, procedure, application, end user, and region
- To provide detailed information regarding the major factors influencing market growth (such as drivers, restraints, opportunities, and challenges)
- To analyze the micromarkets with respect to individual growth trends, prospects, and contributions in the market
- To analyze opportunities for stakeholders and provide details of the competitive landscape for market leaders
- To forecast the size of the market segments with respect to five regions: North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa
- To profile key players and analyze their market shares
- To analyze competitive developments such as product launches, agreements, expansions, and acquisitions
- To benchmark players within the market using the proprietary “Company Evaluation Matrix” framework, which analyzes market players based on various parameters within the broad categories of business and product excellence strategy
Available customizations:
Geographic Analysis
With the given market data, MarketsandMarkets offers customizations as per your company’s specific needs. The following customization options are available for the report:
- Further breakdown of the Rest of Europe tumor ablation market into Russia, Switzerland, Denmark, Austria, and others
- Further breakdown of the Rest of Latin America tumor ablation market into Argentina, Colombia, Chile, Ecuador, and others
- Further breakdown of the Rest of Asia Pacific tumor ablation market into Malaysia, Singapore, New Zealand, and others
- Market share analysis, by region (North America and Europe), which provides market shares of the top 3-5 key players in the tumor ablation market
- Competitive leadership mapping for established players in the US
Personalize This Research
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
Let Us Help You
- What are the Known and Unknown Adjacencies Impacting the Tumor Ablation Market
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
Director of Market Insights, Data and Analytics
SFI Health,
Leading Pharmaceutical Company
We at SFI Health approached MarketsandMarkets for an Opportunity Assessment on "Incidence and Prevalence of Focus Indications" as we wanted to know the most attractive HCPs like Physician, Functional MD, Naturopath and Pharmacist. The project was critical for us to ensure our focus on the right target which would enable sustainable growth and profitability for SFI Health. The business insights provided exceeded our expectations and we were extremely impressed. The team at MarketsandMarkets is highly professional and detail oriented and very well understood our business needs. MarketsandMarkets offers a unique combination of expertise and dedicated engagement model. We identified 2 new products to be launched in coming months, based on the research findings provided by MarketsandMarkets. We are happy with the services and would strongly recommend MarketsandMarkets to my peers in the industry.
Head of Commercial Analytics
Qualicaps,
Leading Pharmaceutical Company
We partnered with MarketsandMarkets for an assessment study on hard empty capsules. The team was extremely professional in understanding our business requirements and we received timely responses to all our queries. The market intelligence and the recommendations has met our business requirements. We were extremely impressed to see the final study results; it really exceeded our expectations. The market intelligence offered by MarketsandMarkets, and clarity on next steps will help us achieve our business objective for the Year 2021. We are happy with the services and would strongly recommend MarketsandMarkets to my peers in the industry.
Senior Director Business Development & Innovation
Bracco Diagnostics Inc.,
Italian Multinational in life sciences sector and a World Leader in imaging diagnostics
We were pleased with targeted insights that MarketsandMarkets identified from a custom study on the 'Radiation Dose Management Solutions Market'. Your team identified and characterized the market participants as well as underlying trends accurately. This study was useful to Bracco in formulating business strategies for our dose monitoring product lines and we thank MarketsandMarkets for the job well done.
Market Development and Strategy Manager
3M Health Information Systems,
Leader in Health care Coding, Payment & Analytics Solutions.
The value for our organization comes from three things: depth of research, specificity of segments and being easy to work with. As important as the first two are, the third can't be underestimated. MarketsandMarkets, maybe more than any other research vendor, wants to know what is top of mind for our team and what big questions we are grappling to answer.
Their customer first approach and high value engagement model, have given us great analysis and excellent value for money
Схожие новости
Классификация: Пресс-релизы. Схожих патентов: 0. Схожих новостей: 10. Тональность: 0. Информативность: 12.28. Источник: www.marketsandmarkets.com.